Multiplexed nucleic acid self-test for reproducible and sensitive HIV detection
Active Definitive Contract Awarded Last action
- Contract number
- 75N93025C00029
- Awardee
-
Vivid Bioinnovations, PBC UEI Q1NZN4P95F83
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $595,337
Award facts
- Opportunity
-
- SBIRPHS20251 Solicitation number
- Contract value 23% obligated
-
- $595,337.00 Current, with exercised options
- $2,566,049.00 Potential, with all options
- Completion date 29% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 12 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Francisco, CA 94107, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2.57 million Small Business Innovation Research (SBIR) Phase I contract to Fluid Discovery, Inc., a San Francisco-based microfluidics and biotechnology company, to develop a multiplexed nucleic acid self-test for reproducible and sensitive HIV detection. Awarded on September 1, 2025, and set aside for small businesses, this firm-fixed-price contract represents NIAID's investment in innovative diagnostic technologies for infectious disease detection. The contract performance will take place in San Francisco, California, with an ultimate completion date of August 31, 2029.
Fluid Discovery, Inc. brings established expertise in advanced microfluidic platforms and diagnostic innovation to this engagement, building on prior SBIR funding from NIAID for related HIV diagnostic work. The company's focus on precision fluid handling, genomics, and biomedical research positions it to develop a practical self-testing solution that addresses critical gaps in HIV screening accessibility and accuracy. This award exemplifies NIAID's commitment to supporting small business-driven research that advances diagnostic capabilities for infectious diseases through cutting-edge biotechnology platforms.
Quick answers
Who was awarded contract 75N93025C00029?
75N93025C00029 was awarded to Vivid Bioinnovations, PBC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2025.
How much is contract 75N93025C00029 worth?
The government has obligated $595,337 on 75N93025C00029. Its potential value, with all options, is $2,566,049.
Was contract 75N93025C00029 competed?
The extent of competition for 75N93025C00029 was full and open competition after exclusion of sources. The government received 12 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award